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Objective: To establish the cardiovascular (CV) morbidity and associated risk factors for CV disease (CVD) in
Spanish patients with chronic inflammatory rheumatic diseases (CIRD) and unexposed individuals attending
rheumatology clinics.
Methods: Analysis of data from the baseline visit of a 10-year prospective study [CARdiovascular in
rheuMAtology (CARMA) project] that includes a cohort of patients with CIRD [rheumatoid arthritis (RA),
ankylosing spondylitis (AS), and psoriatic arthritis (PsA)] and another cohort of matched individuals without
CIRD attending outpatient rheumatology clinics from 67 hospitals in Spain. Prevalence of CV morbidity, CV
risk factors, and systematic coronary risk evaluation (SCORE) assessment were analyzed.
Results: A total of 2234 patients (775 RA, 738 AS, and 721 PsA) and 677 unexposed subjects were included.
Patients had low disease activity at the time of recruitment. PsA patients had more commonly classic CV risk
factors and metabolic syndrome features than did the remaining individuals. The prevalence of CVD was
higher in RA (10.5%) than in AS (7.6%), PsA (7.2%), and unexposed individuals (6.4%). A multivariate analysis
adjusted for the presence of classic CV risk factors and disease duration revealed a positive trend for CVD in RA
(OR ¼ 1.58; 95% CI: 0.90–2.76; p ¼ 0.10) and AS (OR ¼ 1.77; 95% CI: 0.96–3.27; p ¼ 0.07). Disease duration in
all CIRD groups and functional capacity (HAQ) in RA were associated with an increased risk of CVD (OR ¼
2.15; 95% CI: 1.29–3.56; p ¼ 0.003). Most patients had a moderate CV risk according to the SCORE charts.
Conclusions: Despite recent advances in the management of CIRD, incidence of CVD remains increased in
Spanish subjects with CIRD attending outpatient rheumatology clinics.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).r HS Journals, Inc. This is an open
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González-Gay).Introduction
The prevalence of cardiovascular disease (CVD) in chronic
inflammatory rheumatic diseases (CIRDs) is higher than in the
general population [1]. This results from the compound effect of
traditional cardiovascular (CV) risk factors along with chronic
inflammation and a genetic component [2,3].access article under the CC BY-NC-ND license
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matory rheumatic disease associated with accelerated atheroscle-
rosis and increased risk of CV death [1,3–7]. Different studies have
shown a higher incidence of CV events and CV mortality in RA
patients compared to people of the same age and sex [7–9],
similarly to what occurs in type 2 diabetes [10,11]. Overall, patients
with RA have a 2–3-fold higher risk of myocardial infarction, even
in the absence of traditional CV risk factors, as well as a higher rate
of CV mortality (up to 50%) [8,9,12,13].
Consistent with data described in RA, patients with spondy-
loarthropathies also have a higher risk of CVD than the general
population [14,15]. CVD and CV mortality are more common in
patients with PsA compared to the general population [16–18].
Besides traditional CV risk factors, the presence of severe psoriasis
is an important predictor of CVD in these patients [18]. Therefore,
although the role of classic CV risk factors cannot be ruled out [16],
the disease by itself appears to be a predictor of CV events, since
patients with PsA exhibit increased subclinical atherosclerosis
regardless of the presence of classic CV risk factors [19,20].
Ankylosing spondylitis (AS) has also been associated with 1.5–
2.0-fold higher mortality rate compared to the general population,
which is in great part due to CV complications [14,21,22].
Experts in the field have reiterated the need for adequate
stratification of CV risk in patients with CIRD. In this regard, a
task force from the European League Against Rheumatism (EULAR)
has recommended assessing the risk of CV on an annual basis
using the National Guidelines for RA patients [23]. In its absence,
the Systematic Coronary Risk Evaluation (SCORE) function model
is recommended. The SCORE system estimates the 10-year risk of a
fatal atherosclerotic event, including heart attack, stroke, or other
occlusive arterial disease and sudden cardiac death [24,25].
EULAR’s expert panel stated that the same CV risk stratification
procedure should also be applicable to AS and PsA. Risk charts
used for the general population, however, may underestimate the
actual CV risk in patients with rheumatic diseases. Many RA
patients classified as having a moderate risk of CV according to
SCORE risk charts had severe atherosclerotic disease. This was
manifested by the presence of carotid plaques, when non-invasive
tools such as carotid ultrasound were used to assess CV risk in
these patients [26,27].
Recent studies have emphasized that tight control of the
disease leads to a reduction in the rate of CVD in patients with
rheumatic diseases. This is especially true in cases of RA where
methotrexate and especially anti-TNF-α drugs have been associ-
ated with lowering the risk of CV events [28–30]. Thus, one issue
of potential relevance may be the need to establish a CV risk
profile for patients with CIRD, with periodic follow-up at rheuma-
tology outpatient clinics. Under such a program, such patients
would receive active treatment, many of them undergoing biologic
therapy, and, due to this, would not have in most cases active
disease.
Having taken all these considerations together, we aimed in the
present study to establish the CV morbidity and associated risk
factors for CVD in Spanish patients included in the basal visits of
the CARdiovascular in rheuMAtology (CARMA) project, a multi-
center study designed to evaluate CVD in RA, AS, and PsA subjects
attending outpatient rheumatology clinics.Methods
Study design
Descriptive analysis of baseline data obtained at the first visit
during the CARMA project. This is a 10-year prospective study of a
cohort of patients with CIRD (RA, AS, and PsA) and a cohort ofmatched subjects without CIRD attending rheumatology clinics
from 67 hospitals in Spain. The purpose of this project is to
establish the CV risk profile of Spanish patients with CIRD.
Patient recruitment
Patients with CIRD and individuals with non-inflammatory
rheumatic diseases attending outpatient rheumatology clinics
from the participating hospitals were invited to take part in the
study. The period of recruitment was July 2010 to January 2012.
A probabilistic cluster sampling that ensured that the different
rheumatology units in Spain had equal probabilities of being
chosen was carried out. We randomly selected 67 Spanish centers
with rheumatology units from the database of the Spanish Society
of Rheumatology (SER). Recruitment was done by the inclusion of
consecutive patients with any of the three aforementioned con-
ditions, regardless of disease severity or duration. The recruited
patients fulfilled one of the following inclusion criteria: the 1987
American College of Rheumatology Classification Criteria for RA
[31], the modified New York Criteria for Definite AS [32], or the
Moll and Wright Criteria for PsA [33].
Exposed and unexposed cohorts were matched by age (75
years) and sex at a ratio of 1:1. At the end of the recruitment
period, 2986 patients who had met the inclusion criteria had been
invited to participate. Of them, 75 declined to participate in the
study. The statistical power was estimated using the remaining
2911 patients (775 RA, 738 AS, 721 PsA, and 677 unexposed
individuals). The percentage of patients with a SCORE Z 5% was
6% in the unexposed subjects and 12% in the RA cohort. Based on
this assumption, the power of the sample numbering 2911
individuals to detect a statistically significant risk difference of
6%, between the cohorts, was 0.98.
Variables and operative definitions
Both the cohorts were evaluated following international pro-
tocols, including standardized definitions and validated question-
naires. Continuous online and in situ monitoring of data was
performed to verify the quality of the information.
The main variables analyzed were the presence of CV events
and the CV risk SCORE. CV events included ischemic heart disease,
stroke, peripheral arterial disease, and heart failure. To calculate
the CV risk according to the SCORE function, we assessed data on
sex, age, smoking, systolic blood pressure (mmHg), and total
cholesterol (mg/dL). The risk SCORE was calculated for people
aged 40 years and older without CV events. Risk estimates were
generated in chart form for both high- and low-risk regions in
Europe. Spain was included in the low-risk group [24,25].
Secondary variables were as follows: (1) traditional (classic) CV
risk factors (hypertension, dyslipidemia, obesity, smoking, and
diabetes); (2) parameters of inflammation and disease activity;
(3) sociodemographic variables, comorbidities, and laboratory
parameters; and (4) potential confounding factors (disease
severity, duration of disease, and therapies). Operative definitions
of the primary and secondary variables can be found in Table S1
of the Supplementary material. Variables related to inflammatory
activity and severity of CIRD can be found in Supplementary
Table S2.
Statistical analysis
Numerical variables with normal distribution were expressed
as mean and standard deviations. Variables not normally
distributed were expressed as median and interquartile ranges
(IQR ¼ p25–p75). Absolute and relative frequencies were calcu-
lated for qualitative variables. Prevalence, in conjunction with a
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events, was also calculated. SCORE function was calculated for
each group. Bivariate analysis was conducted to compare socio-
demographic characteristics, traditional CV risk factors, and
clinical features of each of the CIRD. The dependent variable
was the medical history of CV events (presence or absence).
Numerical variables were assessed using the Student t test or the
Mann–Whitney U test. Qualitative variables were assessed by a
Chi-square test, Yates correction, or Fisher exact test in 2 
2 tables.
To study the association between CV events and CIRD, logistic
regression models were constructed by calculating odds ratios
(OR) and adjusting for potentially confounding factors. The same
procedure was carried out to identify specific features of RA, AS,
and PsA. The selection of independent variables in the multivariate
models was based on clinical judgments and those with p o 0.20
in the bivariate analysis, using the ENTER method for each of the
models, were included.
All analyses were performed using the SPSS 21.0 statistical
program. In the bivariate analysis, statistical significance was
assumed at p o 0.05, whereas in the multivariate models, it was
assumed to be p r 0.10. This study was performed following the
principles outlined in the Helsinki Declaration, and the study
protocol was approved by the Ethics Committee for Clinical
Research of Galicia, Spain.Table 1
Sociodemographic features, traditional cardiovascular risk factors, and clinical character
Variables Rheumatoid arthritis
(n ¼ 775)
Ankylo
(n ¼ 7
Sociodemographic features
Age at inclusion, years, mean (SD) 57.1 (12.3) 48.1 (1
Age at the beginning of disease, years, mean (SD) 45.8 (13.4) 29.7 (1
Sex, female, n (%) 581 (75.0) 200 (2
Educational level, n (%)
Elementary 467 (60.9) 318 (4
Secondary/university 300 (39.1) 416 (5
Traditional CV risk factors
BMI, kg/m2, mean (SD) 26.9 (4.8) 27.4 (4
Abdominal perimeter, mean (SD) 93.7 (7.0) 96.3 (1
Hypertension, n (%) 236 (30.5) 190 (2
Hypercholesterolemia, n (%) 238 (30.7) 199 (2
Diabetes, n (%) 60 (7.8) 56 (7
Obesity (BMI Z 30), n (%) 180 (23.2) 186 (2
Smoking status, n (%)
Current smokers 189 (24.4) 254 (3
Past smokers 202 (26.1) 240 (3
Never smokers 384 (49.5) 244 (3
Clinical characteristics
Disease duration, years 8.0 (3.0–14.0) 15.0 (8
DAS28-ESR 3.1 (2.3–4.0) –
BASDAI (0–10) – 3.5 (1
HAQ (1–3) 0.5 (0.1–1.1) –
BASFI (0–10) – 3.1 (1
ESR, mm/first hour 17.0 (9.0–29.0) 10.0 (6
CRP, mg/L 3.1 (1.2–8.0) 3.6 (1
RF positive, n (%) 528 (68.1) –
ACPA positive, n (%) 482 (62.2) –
HLA-B27, n (%) – 561 (7
Erosions (RA), n (%) 352 (45.4)
Biologic DMARD, n (%) 313 (40.4) 349 (4
Synthetic DMARD, n (%) 674 (87.0) 239 (3
NSAID, n (%) 309 (39.9) 431 (5
GC, n (% ever treated) 357 (46.1) 59 (8
Data expressed as median (IQR) unless specified. Categorical variables are expressed as nu
peptide antibodies; BASDAI (0–10): Bath Ankylosing Spondylitis (AS) Disease Activity Sco
protein; CV: cardiovascular; DAS28-ESR: Disease Activity Score using 28 joints-eryth
glucocorticoids; HAQ (0–3): Health Assessment Questionnaire; HLA-B27: histocomp
rheumatoid arthritis; RF: rheumatoid factor.Results
Demographic characteristics and traditional CV risk factors
A total of 2911 patients were included in the study: 775 patients
with RA, 738 with AS, 721 with PsA, and 677 unexposed individuals
with the following diseases: osteoarthritis (30%), osteoporosis
(15.2%), and other non-inflammatory diseases (54.8%).
The demographic characteristics are summarized in Table 1.
The mean age of patients with RA was higher than in those from
the other groups. Although patients with AS were younger, the
duration of disease was longer than in the other groups. Unex-
posed individuals had a higher percentage of secondary and
university education (65.9%) than the groups with CIRD, which
included more patients with only elementary level education (p o
0.001).
Overall, patients with PsA had more commonly classic CV risk
factors and features of metabolic syndrome than individuals in the
other groups. Smoking history was more commonly observed in
those with AS (Table 1).
Disease activity and therapy
Table 1 shows the most relevant data related to disease activity
and severity in the different groups of the study. In general,istics of the population included in the study
sing spondylitis
38)
Psoriatic arthritis
(n ¼ 721)
Unexposed matched cohort
(n ¼ 677)
p
1.7) 51.8 (12.0) 54.0 (12.4) o0.001
1.8) 39.5 (13.3) 48.5 (12.4) o0.001
7.1) 327 (45.4) 437 (64.5) o0.001
3.3) 331 (46.3) 229 (34.1)
6.7) 383 (53.7) 443 (65.9) o0.001
.4) 28.2 (4.7) 26.7 (4.4) o0.001
2.9) 97.6 (13.0) 93.5 (12.9) o0.001
5.7) 213 (29.5) 158 (23.3) 0.008
7) 257 (35.6) 224 (33.1) 0.003
.6) 66 (9.2) 34 (5.0) 0.030
5.2) 209 (29.1) 147 (21.8) 0.010
4.4) 157 (21.8) 143 (21.2)
2.5) 227 (31.5) 176 (26.0) o0.001
3.1) 337 (46.7) 357 (52.8)
.0–26.0) 9.0 (4.0–16.0) 2.0 (0.0–6.0) o0.001
2.9 (2.0–3.8) – 0.002
.7–5.3) – – –
0.4 (0.0–0.9) – o0.001
.3–5.2) – – –
.0–21.0) 12.0 (6.0–21.0) 10.0 (5.0–18) o0.001
.6–8.9) 2.9 (1.4–6.1) 1.9 (1.3–3.3) o0.001
– – –
– – –
6) – – –
–
7.4) 300 (41.7) – o0.001
2.4) 536 (74.5) – o0.001
8.5) 329 (45.9) 142 (21.0) o0.001
.0) 129 (17.9) – o0.001
mber (n) and percentage (%). SD: standard deviation; ACPA: anti-cyclic citrullinated
re; BASFI (0–10): Bath AS Functional Index; BMI: body mass index; CRP: C-reactive
rocyte sedimentation rate; DMARD: disease-modifying antirheumatic drugs; GC:
atibility antigen HLA-B27; NSAID: non-steroidal anti-inflammatory drugs; RA:
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time of recruitment. In keeping with these findings, acute-phase
reactant [erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP)] values and functionality scores [Health Assessment
Questionnaire (HAQ) and Bath Ankylosing Spondylitis Functional
Index (BASFI)] showed low values. In this regard, almost half of the
patients with CIRD were undergoing biologic therapies at that
time. Nonetheless, almost half of the patients with RA had
received or were taking low-dose prednisone.
Prevalence of CV events
Figure 1 shows the prevalence of CVD in the different cohorts.
The overall prevalence of CVD in RA was 10.5% (20.1% in men and
7.2% in women). A lower prevalence was found in the three other
groups (AS, 7.6%; PsA, 7.2%; and unexposed individuals, 6.4%). In
most cases, CV events occurred after diagnosis of CIRD (Fig. 1).
Clinical risk factors associated with CVD
Bivariate analysis showed direct correlations between the age
at symptom onset, disease duration, educational level, smoking
habit (greater risk in ex-smokers), and the development of CV
events (Table 2). This was also the case with traditional CV risk
factors such as diabetes, hypertension, and hypercholesterolemia
in both CIRD patients and unexposed individuals (Fig. 2). Interest-
ingly, HAQ was associated with the occurrence of CV events in
both RA and PsA patients. Furthermore, an association between CV
events and structural damage, manifested by the presence ofFig. 1. Prevalence of cardiovascular events in both exposed (RA, AS, and PsA) and une
disease diagnosis (for each disease). Empty boxes represent total prevalence at the timeerosions in RA and coxitis in patients with AS, was also found
(Table 2).
Multivariate analysis showed a direct correlation between RA
and risk of CVD (adjusted OR ¼ 1.58; 95% CI: 0.90–2.76; p ¼ 0.10).
Similar results were observed in patients with AS (adjusted OR ¼
1.77; 95% CI: 0.96–3.27; p ¼ 0.07). Additional associations with
CVD were the age at recruitment, male gender, past history of
smoking in AS, disease duration, and some traditional CV risk
factors (Table 3). Hypertension and hypercholesterolemia were
significantly associated with CVD in all groups. However, diabetes
was found to be significantly associated only with RA (adjusted
OR ¼ 2.56; 95% CI: 1.06–6.18; p ¼ 0.04).
Multivariate analysis for each of the CIRD groups confirmed
associations with disease duration and most CV risk factors.
Nevertheless, association with HAQ was only observed in RA
patients (adjusted OR ¼ 2.15; 95% CI: 1.29–3.56; p o 0.01)
(Table 3).
SCORE results
To calculate the CV risk according to SCORE charts, only
patients aged 40 years and older without a previous history of
CV events at the time of assessment were included in the analysis.
Thus, 52 patients with such a history of CV events were excluded.
The frequency of a high or very high CV risk (Z5%) was greater
in the RA cohort (21%) compared to other groups (14.4% in PsA
patients and unexposed individuals and 12% in AS patients).
Nevertheless, most CIRD patients and unexposed individuals
were included within the category of moderate CV risk as the
SCORE ranged between Z1% and o5% (Table 4). The highestxposed cohorts. Gray boxes represent prevalence of cardiovascular events before
of recruitment.
Table 2
Bivariate analysis according to each specific entity and the occurrence of cardiovascular events
Variables All patients Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Unexposed matched cohort
Total CVE No CVE CVE No CVE p CVE No CVE p CVE No CVE p ECV No ECV p
Female, n (%) 1520 (53.2) 51 (37.5) 1469 (53.9) 25 (58.1) 545 (76.9) 0.009 4 (10.5) 193 (27.9) 0.031 9 (30.0) 312 (45.8) 0.129 13 (52.0) 419 (65.4) 0.246
Age at onset of
symptoms,
years, mean
(SD)
40.5 (14.5) 45.8 (16.9) 40.3 (14.3) 49.1 (13.3) 45.1 (13.1) 0.053 34.9 (13.9) 29.3 (11.5) 0.019 45.6 (17.7) 39.0 (12.9) 0.051 56.8 (17.1) 48.1 (12.0) 0.001
Educational
level, n (%)
Elementary 1652 (58.3) 102 (75.0) 1550 (57.4) 35 (81.4) 473 (67.5) 0.083 22 (57.9) 392 (57.0) 1.000 25 (83.3) 394 (58.4) 0.011 20 (80.0) 291 (45.8) 0.002
Secondary/
university
1184 (41.7) 34 (25.0) 1150 (42.6) 8 (18.6) 228 (32.5) 16 (42.1) 296 (43.0) 5 (16.7) 281 (41.6) 5 (20.0) 345 (54.2)
Smoking, n (%)
Never 1300 (45.5) 55 (40.4) 1245 (45.7) 23 (53.5) 349 (49.2) 0.002 4 (10.5) 236 (34.1) o0.001 13 (43.3) 321 (47.1) 0.097 15 (60.0) 339 (53.0) 0.516
Past
smokers
823 (28.8) 64 (47.1) 759 (27.9) 18 (41.9) 177 (25.0) 25 (65.8) 213 (30.8) 14 (46.7) 206 (30.2) 7 (28.0) 163 (25.5)
Current
smokers
735 (25.7) 17 (12.5) 718 (26.4) 2 (4.7) 183 (25.8) 9 (23.7) 243 (35.1) 3 (10.0) 154 (22.6) 3 (12.0) 138 (21.6)
Family history
of IHD, n (%)
349 (12.4) 21 (15.6) 328 (12.2) 8 (18.6) 83 (11.8) 0.274 5 (13.2) 94 (13.7) 1.000 5 (16.7) 72 (10.7) 0.362 3 (12.5) 79 (12.7) 1.000
Obesity, n (%) 702 (24.6) 51 (37.5) 651 (24.0) 10 (23.3) 160 (22.6) 1.000 17 (44.7) 166 (24.0) 0.007 14 (46.7) 189 (27.8) 0.043 10 (40.0) 136 (21.3) 0.049
Diabetes, n (%) 198 (6.9) 30 (22.1) 168 (6.2) 10 (23.3) 44 (6.2) o0.001 8 (21.1) 44 (6.4) 0.004 9 (30.0) 53 (7.8) 0.001 3 (12.0) 27 (4.2) 0.097
Hypertension,
n (%)
755 (26.4) 97 (71.3) 658 (24.2) 28 (65.1) 190 (26.8) o0.001 24 (63.2) 160 (23.1) o0.001 24 (80.0) 179 (26.3) o0.001 21 (84.0) 129 (20.1) o0.001
Hypercholes-
terol, n (%)
886 (31.0) 99 (72.8) 787 (28.9) 23 (53.5) 203 (28.6) 0.001 31 (81.6) 162 (23.4) o0.001 26 (86.7) 223 (32.7) o0.001 19 (76.0) 199 (31.0) o0.001
Disease
duration,
years
8.0 (3.0–16.0) 15.5 (7.0–27.7) 8.0 (3.0–15.0) 13.0 (8.0–21.0) 8.0 (3.0–14) o0.001 23 (13.0–32.5) 15.0 (8.0–26) 0.002 19 (6.7–28.2) 9.0 (4.0–16.0) 0.002 5.0 (0.5–17.0) 2.0 (0.0–6.0) 0.017
ESR, mm/first
hour
12.0 (6.0–22) 12.0 (6.7–24) 12.0 (6.0–22.0) 18.0 (7.7–28.2) 17.0 (9.0–30.0) 0.563 10.5 (6.7–19.2) 10.0 (6.0–21) 0.694 10.0 (7–30.2) 12.0 (6.0–20.5) 0.491 9.0 (4.2–23.7) 10.0 (5.0–18.0) 0.722
CRP, mg/L 2.9 (1.1–6.6) 4.0 (1.3–8.0) 2.9 (1.1–6.4) 2.3 (1.0–6.1) 3.1 (1.2–8.0) 0.217 6.0 (2.6–7.8) 3.4 (1.5–8.9) 0.181 3.6 (1.5–8.5) 2.9 (1.3–6.0) 0.334 2.0 (1.1–14.5) 1.9 (1.0–3.2) 0.040
NSAID, n (%) 1198 (41.9) 54 (39.7) 1144 (42.0) 17 (39.5) 283 (39.9) 1.000 22 (57.9) 407 (58.8) 1.000 10 (33.3) 319 (46.8) 0.206 5 (20.0) 135 (21.1) 1.000
Glucocorti-
coids, n (%)
526 (24.0) 31 (27.7) 495 (23.8) 23 (53.5) 319 (45.0) 0.353 2 (5.3) 56 (8.1) 0.760 6 (20.0) 120 (17.6) 0.929 – – –
DMARD, n (%) 1418 (49.6) 76 (55.9) 1342 (49.3) 38 (88.4) 615 (86.7) 0.940 14 (36.8) 223 (32.2) 0.679 24 (80.0) 504 (74.0) 0.602 – – –
Biologics, n (%) 951 (33.3) 43 (31.6) 908 (33.3) 21 (48.8) 285 (40.2) 0.337 13 (34.2) 333 (48.1) 0.132 9 (30.0) 290 (42.6) 0.239 – – –
RFþ , n (%) – – – 33 (76.7) 542 (76.4) 1.000 – – – – – – – – –
ACPAþ , n (%) – – – 25 (58.1) 421 (59.4) 0.999 – – – – – – – – –
Erosions, n (%) – – – 28 (65.1) 312 (44.0) 0.011 – – – – – –
DAS28-ESR 3.0 (2.2–3.9) 3.1 (2.3–4.1) 3.0 (2.1–3.9) 3.2 (2.4–4.2) 3.0 (2.3–4.0) 0.260 – – – 2.9 (2.1–3.5) 2.9 (2.0–3.8) 0.806 – – –
HAQ (1–3) 0.5 (0.0–1.1) 0.7 (0.3–1.6) 0.5 (0.0–1.1) 1.1 (0.5–1.6) 0.5 (0.1–1.1) o0.001 – – – 0.7 (0.1–1.2) 0.4 (0.0–0.9) 0.028 – – –
HLA-B27, n (%) – – – – – – 28 (73.7) 527 (76.2) 0.879 – – – – –
Coxitis, n (%) – – – – – – 29 (76.3) 385 (55.6) 0.019 – – – – –
BASDAI (1–10) – – – – – – 2.8 (1.5–4.7) 3.5 (1.8–5.3) 0.411 – – – – – –
BASFI (1–10) – – – – – – 3.4 (1.1–6.2) 3.0 (1.3–5.1) 0.793 – – – – – –
Enthesopathy,
n (%)
417 (29.4) 19 (28.4) 398 (29.4) – – – 15 (39.5) 225 (32.8) 0.500 4 (13.3) 173 (25.9) 0.210 – – –
Data expressed as median and interquartile range (IQR) unless specified. Categorical variables are expressed as number (n) and percentage (%). SD: standard deviation; ACPA: anti-cyclic citrullinated peptide antibodies; BASDAI (0–
10): Bath Ankylosing Spondylitis (AS) Disease Activity Score; BASFI (0–10): Bath AS Functional Index; BMI: body mass index; CRP: C-reactive protein; CVE: cardiovascular events; DAS28-ESR: Disease Activity Score using 28 joints-
erythrocyte sedimentation rate; DMARD: disease-modifying antirheumatic drugs; HAQ (0–3): Health Assessment Questionnaire; HLA-B27: histocompatibility antigen HLA-B27; IHD: ischemic heart disease; NSAID: non-steroidal
anti-inflammatory drugs; RA: rheumatoid arthritis; RF: rheumatoid factor.
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Fig. 2. Prevalence of hypertension, hypercholesterolemia, and acute myocardial infarction in the CIRD cohort (Exp) and in the unexposed matched cohort (Unexp). (Upper
panel) males and (Lower panel) females. HT: hypertension; HYPERCHOL: hypercholesterolemia; MI: myocardial infarction.
S. Castañeda et al. / Seminars in Arthritis and Rheumatism 44 (2015) 618–626 623mean basal SCORE results were found in men with RA, followed by
those with PsA and unexposed subjects. Additional information is
shown in Table 4.Discussion
Baseline results from the CARMA project indicate that the risk
of CVD in Spanish patients with CIRD attending outpatient
rheumatology clinics is higher than in non-inflammatory disease
patients. This seems to be particularly true for RA and AS patients.
In this regard, although in the adjusted models the risk for CV
events in RA and AS groups reached levels that may be considered
marginally significant, we feel that they are of considerable value.
Patients from the study were periodically followed by rheumatol-
ogists at medical centers and at the time of recruitment had
generally mild disease activity. Most of them had low levels of
disability, and the acute-phase reactants were within the normal
range. Taking all these considerations together, we believe that
these factors may potentially exert some influence in decreasing
the actual prevalence of CVD in Spanish CIRD patients.
In line with the above, it is interesting to note the high number
of patients undergoing biologic therapy, which exceeded 40% in
the three inflammatory conditions included in the CIRD cohort.
This fact may explain the reasonable degree of control over the
disease achieved in our patients. This may have lead, in turn, to a
reduction in the inflammatory burden and, consequently, to a
decrease in the prevalence of CV events. Interestingly, results from
the British Society for Rheumatology Biologics Register (BSRBR)
have revealed that the risk of myocardial infarction is lower inpatients RA who respond to anti-TNF-α therapy compared to non-
responders [29]. Since chronic inflammation plays a pivotal role in
the increased risk of subclinical atherosclerosis and CV morbidity
and mortality in RA [3,4,34], lessening the CV risk associated with
anti-TNF-α therapy in other studies highlights the potential car-
dioprotective effect of these biologic agents when mediated by
reductions in the inflammatory burden [30].
As previously reported [2,16], classic CV risk factors were
associated with CVD in this Spanish cohort of CIRD patients.
Furthermore, disease duration was also associated with an increased
risk of CVD in those patients included in the CARMA project. This is
keeping with various studies that have supported the relevance of
disease duration in the risk of CVD in RA patients [6,35].
As observed in the general population, the prevalence of CVD in
patients with CIRD included in the Spanish study was higher in
men. In our study, we did not observe a significant association
between the educational levels and CVD in these patients.
Since in the general population both active and past smokers
have a higher prevalence of myocardial infarction than non-
smokers, the higher CV risk among past smokers in this cohort
of CIRD patients, in particular in the group of AS, may be in part
the result of a reversal causality, specifically a previous history of
CV events, which is one of the main reasons for quitting smoking.
A point of special interest in chronic inflammatory diseases is
the paradoxical association between lipids and CVD risk. Although
in the general population the risk to develop atherosclerosis
increases progressively with increasing low-density lipoprotein
(LDL) cholesterol levels and declines with increasing levels of
high-density lipoprotein (HDL) cholesterol, the presence of a
proinflammatory state leads to a decrease of total, HDL, and LDL
Table 3
Multivariate analysis of cardiovascular disease in the cohort of patients with chronic inflammatory rheumatic diseases
Variables All patients (n ¼ 2234) Rheumatoid arthritis (n ¼ 775) Ankylosing spondylitis (n ¼ 738) Psoriatic arthritis (n ¼ 721)
ORc
(95% CI)
ORadj
(95% CI)
p ORc
(95% CI)
ORadj
(95% CI)
p ORc
(95% CI)
ORadj
(95% CI)
p ORc
(95% CI)
ORadj
(95% CI)
p
Disease (ref.
unexposed)
RA 1.56 (0.94–2.58)a 1.58 (0.90–2.76) 0.100 – – – – – – – – –
AS 1.41 (0.84–2.36) 1.77 (0.96–3.27) 0.068 – – – – – – – – –
PsA 1.13 (0.66–1.94) 0.96 (0.53–1.76) 0.905 – – – – – – – – –
Age at inclusion 1.09 (1.07–1.11)b 1.07 (1.05–1.09) o0.001 – – – – – – – – –
Age onset of
symptoms
1.02 (1–1.05)a 1.03 (0.99–1.07) 0.122 1.04 (1.01–1.07)b 1.08 (1.03–1.13) 0.001 1.04 (1.01–1.07)b 1.09 (1.04–1.15) 0.001
Sex (ref. male) 0.51 (0.36–0.73)b 0.46 (0.29–0.73) 0.001 0.42 (0.22–0.79)b 0.32 (0.14–0.76) 0.010 0.30 (0.11–0.87)b 0.4 (0.12–1.34) 0.137 0.51 (0.23–1.12)a 2.25 (0.82–6.15) 0.114
Educational level
(ref.
elementary)
0.45 (0.30–0.67)b 0.77 (0.5–1.20) 0.254 0.47 (0.22–1.04)a 0.63 (0.26–1.53) 0.306 0.96 (0.5–1.87) 1.71 (0.78–3.76) 0.180 0.28 (0.11–0.74)b 0.58 (0.19–1.84) 0.357
Smoking (ref. never)
Smokers 0.54 (0.31–0.93)b 0.7 (0.37–1.29) 0.251 0.17 (0.04–0.71)b 0.26 (0.05–1.25) 0.093 219 (0.66–7.19) 1.64 (0.44–6.08) 0.104 0.48 (0.14–1.71) 1.35 (0.31–5.91) 0.690
Past smokers 1.91 (1.32–2.77)b 1.42 (0.9–2.25) 0.132 1.54 (0.81–2.94) 1.68 (0.72–3.92) 0.229 6.93 (2.37–20.22)b 3.39 (1.05–10.93) 0.041 1.68 (0.7–3.64) 1.84 (0.67–5.06) 0.236
Family history of
IHD (ref. no)
1.33 (0.82–2.14) 1.24 (0.72–2.13) 0.436 1.72 (0.77–3.82) 1.31 (0.53–3.24) 0.563 0.96 (0.36–2.51) 0.84 (0.27–2.66) 0.770 1.67 (0.62–4.49) 2.01 (0.61–6.64) 0.253
Obesity (ref. no) 1.91 (1.33–2.73)b 1.24 (0.83–1.85) 0.304 1.04 (0.50–2.16) 0.76 (0.33–1.76) 0.521 2.56 (1.32–4.98)b 1.57 (0.71–3.49) 0.266 2.27 (1.09–4.74)b 2.07 (0.78–5.45) 0.143
Diabetes (ref. no) 4.30 (2.79–6.65)b 1.40 (0.85–2.29) 0.185 4.58 (2.12–9.90)b 2.56 (1.06–6.18) 0.036 3.93 (1.70–9.08)b 1.15 (0.42–3.12) 0.791 5.08 (2.22–11.64)b 1.27 (0.46–3.47) 0.640
Hypertension
(ref. no)
7.81 (5.33–11.44)b 2.85 (1.86–4.36) o0.001 5.1 (2.66–9.76)b 2.36 (1.12–4.98) 0.024 5.70 (2.88–11.28)b 2.01 (0.89–4.57) 0.095 11.22 (4.51–27.89)b 3.23 (1.15–9.05) 0.026
Hypercholestero-
lemia (ref. no)
6.58 (4.47–9.69)b 4.15 (2.73–6.33) o0.001 2.87 (1.54–5.33)b 2.20 (1.09–4.45) 0.028 14.5 (6.26–33.52)b 8.66 (3.54–21.24) o0.001 13.35 (4.60–38.72)b 6.12 (1.98–19.25) 0.002
Disease duration – – – 1.05 (1.03–1.08)b 1.06 (1.01–1.11) 0.025 1.04 (1.01–1.06)b 1.06 (1.06–1.01) 0.014 1.08 (1.04–1.11)b 1.15 (1.072–1.228) o0.001
HAQ – – – 2.18 (1.44–3.28)b 2.15 (1.29–3.56) 0.003 – – – 2.0 (1.2–3.34)b 1.08 (0.54–2.18) 0.821
Erosions (ref. no) – – – 2.38 (1.25–4.53)b 1.60 (0.78–3.30) 0.202 – – – – – –
Coxitis (ref. no) – – – – – – 2.57 (1.2–5.51)b 1.86 (0.79–4.36) 0.155 – – –
Adjusted for sex, age at inclusion, age at onset of symptoms, educational level, smoking habit, family history of ischemic heart disease (IHD), disease duration, erosions (in RA and PsA), HAQ, and traditional CV risk factors (obesity,
hypertension, diabetes mellitus, and dyslipidemia).
OR: odds ratio; ORc: crude OR; ORadj: adjusted OR.
a Significant variables at 90% confidence interval (CI) (p r 0.10).
b Significant variables at 95% CI (p o 0.05) in the crude, non-adjusted analysis.
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Table 4
Assessment of the SCORE function in the CARMA study population
Traditional cardiovascular risk factorsa Baseline
SCORE
index
(mean)
Sex Smoking Age,
mean
(years)
SBP,
mean
(mmHg)
Cholesterolb
mean (mg/
dL)
Rheumatoid
arthritis
(n ¼ 693)
Male No 64.2 140.9 193.9 4.2
Yes 54.7 135.6 196.2 3.2
Female No 60.1 133.9 209.3 1.3
Yes 53.7 126.4 210.9 0.9
Ankylosing
spondyli-
tis (n ¼
545)
Male No 54.2 133.2 197.1 1.5
Yes 51.6 133.3 207.9 2.4
Female No 54.0 128.5 204.4 0.5
Yes 50.1 127.1 201.6 0.5
Psoriatic
arthritis
(n ¼ 598)
Male No 55.7 135.4 200.1 1.8
Yes 52.9 136.3 200.5 2.8
Female No 56.4 134.9 211.2 0.8
Yes 52.1 125.6 205.2 0.7
Unexposed
subjects
(n ¼ 578)
Male No 57.1 131.5 203.7 2
Yes 53.0 130.9 217.7 2.8
Female No 58.7 127.1 213.0 0.9
Yes 54.2 125.1 219.5 1.0
SCORE: Systematic Coronary Risk Evaluation; SBP: systolic blood pressure.
a Only patients Z40 years of age without previous history of cardiovascular
events (CVE) at the time of assessment were included in the analysis.
b Total cholesterol.
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in the current investigation, hypercholesterolemia was consistently
associated with CVD. Intuitively, this contrasting finding/disparity
is in a way expected in view of the tight control of patients included
in this study with mild disease activity at the time of recruitment.
Interestingly, although in bivariate analysis obesity was asso-
ciated with CV events in AS, PsA, and unexposed subjects, this was
not the case in RA. Further, obesity was not related to CV events in
any of the groups once other risk factors were considered in
multivariable analysis. In this regard, a recent study has shown
that obesity was associated with carotid atherosclerosis in white
patients with RA, but this relationship was explained by metabolic
risk factors [37].
The frequency of positive rheumatoid factor and anti-CCP
antibodies, as well as the presence of radiographic erosions in
the cohort of RA patients of the CARMA project, was similar to
those reported in other series of Spanish RA patients [38,39]. This
was also true of the frequency of HLA-B27 [40]. However, no
significant association between these data and the occurrence of
CVD was found. In addition, although the presence of coxitis was
associated with CVD in the bivariate analysis, this association did
not reach significance in the multivariate analysis. In contrast, an
association of current HAQ with the presence of CV events in RA
was observed both in the bivariate and multivariate analyses. This
finding may be of potential relevance since HAQ reflects damage
accrual over time, which reflects the persistence of a chronic
proinflammatory state leading to increased atherogenic burden. In
this regard, some authors have linked HAQ results with mortality
and long-term structural damage and work disability [41,42].
Moreover, a relationship between HAQ and comorbidity has been
found in RA [43,44]. These studies suggest that high HAQ values
may serve as accurate predictors of mortality and risk of CVD.
Regarding Systematic Coronary Risk Evaluation, the mean SCORE
was higher in patients with CIRD than in the unexposed cohort.
However, most patients were included in the category of moderate
CV risk when SCORE risk charts were used. These results are in
agreement with recent data from a population-based study showing
that approximately 60% of patients with RA fall into the category of
moderate CV risk according to SCORE risk charts. Regrettably, more
than 50% of them had carotid plaques when carotid ultrasoundstudies were performed, indicating that tools generally used for the
stratification of the CV risk in the general population may under-
estimate the actual CV risk in patients with CIRD [26,27]. Interest-
ingly, a recent study has demonstrated that RA patients with active
disease have higher vulnerability of carotid plaques than those in
clinical remission [45]. Therefore, both tight control of the disease
and adequate CV risk stratification should be carried out in patients
with CIRD to minimize the increased risk of CV death [46,47].
The nature of our study may suffer certain limitations, as we
have studied a population periodically assessed at rheumatology
units. This fact possibly reduces the risk of CVD in this cohort of
CIRD patients. Nevertheless, our results indicate that despite
recent advances in the management of chronic inflammatory
diseases, CVD remains increased in Spanish patients with CIRD
attending rheumatology outpatient clinics. Another potential lim-
itation of our study is that the unexposed cohort used for
comparison is not a completely healthy cohort, since it included
patients with chronic diseases such as osteoarthritis and osteopo-
rosis, which by themselves may cause some increase in CV
mortality. Nevertheless, these considerations, despite whatever
limitation they may impose on our study, still underscore the
likelihood that there is an increased risk of CVD in patients with
CIRD, even if they are adequately controlled.
In summary, we present here the baseline analysis of a 10-year
prospective study from a cohort of patients with CIRD attending
outpatient rheumatology clinics in Spain, where the prevalence of
CVD in RA and AS was higher than that observed in an unexposed
cohort.Conclusion
Our results indicate that, despite recent advances in the
management of chronic inflammatory rheumatic diseases, the
prevalence of cardiovascular disease (CVD) remains high in Span-
ish subjects with CIRD who are followed up periodically at
outpatient rheumatology clinics. It is of particular relevance as
almost half of them were receiving biological therapy and most
patients had low disease activity at the time of assessment. Classic
CV risk factors and disease duration are associated with an
increased risk of CVD. Furthermore, HAQ is independently asso-
ciated with the occurrence of CV events in patients with RA.
Surprisingly, most patients with increased prevalence of CV events
had a moderate CV risk according to the SCORE charts.Authors’ contributions
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